Top

Published in:

Open Access 01-07-2015 | Review Article

Comprehensive review of the detection methods for synthetic cannabinoids and cathinones

Authors: Akira Namera, Maho Kawamura, Akihiro Nakamoto, Takeshi Saito, Masataka Nagao

Published in: Forensic Toxicology | Issue 2/2015

Abstract

A number of N-alkyl indole or indazole-3-carbonyl analogs, with modified chemical structures, are distributed throughout the world as synthetic cannabinoids. Like synthetic cannabinoids, cathinone analogs are also abused and cause serious problems worldwide. Acute deaths caused by overdoses of these drugs have been reported. Various analytical methods that can cope with the rapid changes in chemical structures are required for routine analysis and screening of these drugs in seized and biological materials for forensic and clinical purposes. Although many chromatographic methods to analyze each drug have been published, there are only a few articles summarizing these analytical methods. This review presents the various colorimetric detections, immunochemical assays, gas chromatographic–mass spectrometric methods, and liquid chromatographic–mass spectrometric methods proposed for the analysis of synthetic cannabinoids and cathinones.

Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMed

Maxwell JC (2014) Psychoactive substances—some new, some old: a scan of the situation in the US. Drug Alcohol Depend 134:71–77PubMed

Kikura-Hanajiri R, Uchiyama N, Kawamura M, Goda Y (2013) Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol 31:44–53

Chung H, Choi H, Heo S, Kim E, Lee J (2014) Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013. Forensic Toxicol 32:82–88

Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH (2013) Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a 3-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int 233:416–422PubMed

Barratt MJ, Cakic V, Lenton S (2013) Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 32:141–146PubMed

Caudevilla-Gálligo F, Ventura M, Indave Ruiz BI, Fornís I (2013) Presence and composition of cathinone derivatives in drug samples taken from a drug test service in Spain (2010–2012). Hum Psychopharmacol 28:341–344PubMed

Presley BC, Jansen-Varnum SA, Logan BK (2013) Analysis of synthetic cannabinoids in botanical materials: a review of analytical methods and findings. Forensic Sci Rev 25:27–46

Elsohly MA, Gul W, Wanas AS, Radwan MM (2014) Synthetic cannabinoids: analysis and metabolites. Life Sci 97:78–90PubMed

10.

Favretto D, Pascali JP, Tagliaro F (2013) New challenges and innovation in forensic toxicology: focus on the “New Psychoactive Substances”. J Chromatogr A 1287:84–95PubMed

11.

Isaacs RCA (2014) A structure–reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse. Forensic Sci Int 242:135–141PubMed

12.

Zaitsu K, Katagi M, Nakanishi K, Shima N, Kamata H, Kamata T, Nishioka H, Miki A, Tatsuno M, Iwamura T, Sato T, Tsuchihashi H, Suzuki K (2011) Comprehensive analytical methods of the synthetic cannabinoids appearing in the illicit drug market (in Japanese with English abstract). Jpn J Forensic Sci Tech 16:73–90

13.

Logan BK, Reinhold LE, Xu A, Diamond FX (2012) Identification of synthetic cannabinoids in herbal incense blends in the US. J Forensic Sci 57:1168–1180PubMed

14.

Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B (2013) Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 37:284–290PubMed

15.

Hudson S, Ramsey J (2011) The emergence and analysis of synthetic cannabinoids. Drug Test Anal 3:466–478PubMed

16.

Choi H, Heo S, Choe S, Yang W, Park Y, Kim E, Chung H, Lee J (2013) Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC–MS. Anal Bioanal Chem 405:3937–3944PubMed

17.

Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125

18.

Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 31:93–100

19.

Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223–240

20.

Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105–115

21.

Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T (2014) Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol 32:266–281

22.

Cox AO, Daw RC, Mason MD, Grabenauer M, Pande PG, Davis KH, Wiley JL, Stout PR, Thomas BF, Huffman JW (2012) Use of SPME-HS-GC–MS for the analysis of herbal products containing synthetic cannabinoids. J Anal Toxicol 36:293–302PubMedCentralPubMed

23.

Ernst L, Krüger K, Lindigkeit R, Schiebel HM, Beuerle T (2012) Synthetic cannabinoids in “spice-like” herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market. Forensic Sci Int 222:216–222PubMed

24.

Kneisel S, Westphal F, Bisel P, Brecht V, Broecker S, Auwärter V (2012) Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1-pentylindole as an additive in ‘herbal incense’. J Mass Spectrom 47:195–200PubMed

25.

Harris DN, Hokanson S, Miller V, Jackson GP (2014) Fragmentation differences in the EI spectra of three synthetic cannabinoid positional isomers: JWH-250, JWH-302, and JWH-201. Int J Mass Spectrom 368:23–29

26.

DeRuiter J, Smith FT, Abdel-Hay K, Clark CR (2014) Analytical differentiation of 1-alkyl-3-acylindoles and 1-acyl-3-alkylindoles: isomeric synthetic cannabinoids. Anal Chem 86:3801–3808PubMed

27.

Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y (2014) 3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures. Forensic Sci Int 242:72–80PubMed

28.

Ibáñez M, Bijlsma L, van Nuijs ALN, Sancho JV, Haro G, Covaci A, Hernández F (2013) Quadrupole-time-of-flight mass spectrometry screening for synthetic cannabinoids in herbal blends. J Mass Spectrom 48:685–694PubMed

29.

Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A (2013) Gas and liquid chromatography–mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 37:265–276PubMed

30.

Tsujikawa K, Yamamuro T, Kuwayama K, Kanamori T, Iwata YT, Inoue H (2014) Thermal degradation of a new synthetic cannabinoid QUPIC during analysis by gas chromatography–mass spectrometry. Forensic Toxicol 32:201–207

31.

Sekuła K, Zuba D, Stanaszek R (2012) Identification of naphthoylindoles acting on cannabinoid receptors based on their fragmentation patterns under ESI–QTOFMS. J Mass Spectrom 47:632–643PubMed

32.

Kneisel S, Auwärter V (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid–liquid extraction. J Mass Spectrom 47:825–835PubMed

33.

Scheidweiler KB, Huestis MA (2014) Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography–tandem mass spectrometry. J Chromatogr A 1327:105–117PubMedCentralPubMed

34.

Wohlfarth A, Scheidweiler KB, Chen X, Liu H, Huestis MA (2013) Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC–MS/MS and library search. Anal Chem 85:3730–3738PubMed

35.

Kneisel S, Auwärter V, Kempf J (2013) Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test Anal 5:657–669PubMed

36.

Kneisel S, Speck M, Moosmann B, Corneillie TM, Butlin NG, Auwärter V (2013) LC/ESI–MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal Bioanal Chem 405:4691–4706PubMed

37.

Hutter M, Kneisel S, Auwärter V, Neukamm MA (2012) Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J Chromatogr B 903:95–101

38.

Teske J, Weller JP, Fieguth A, Rothämel T, Schulz Y, Tröger HD (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography–tandem mass spectrometry. J Chromatogr B 878:2659–2663

39.

Kacinko SL, Xu A, Homan JW, McMullin MM, Warrington DM, Logan BK (2011) Development and validation of a liquid chromatography–tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol 35:386–393PubMed

40.

Yeakel JK, Logan BK (2013) Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol 37:547–551PubMed

41.

Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwärter V (2011) Development and validation of a liquid chromatography–tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 46:163–171PubMed

42.

Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83:4228–4236PubMedCentralPubMed

43.

Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH (2011) Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem 83:6381–6388PubMedCentralPubMed

44.

de Jager AD, Warner JV, Henman M, Ferguson W, Hall A (2012) LC–MS/MS method for the quantitation of metabolites of eight commonly used synthetic cannabinoids in human urine—an Australian perspective. J Chromatogr B 897:22–31

45.

Yanes EG, Lovett DP (2012) High-throughput bioanalytical method for analysis of synthetic cannabinoid metabolites in urine using salting-out sample preparation and LC–MS/MS. J Chromatogr B 909:42–50

46.

Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:534–544PubMed

47.

Hermanns-Clausen M, Kneisel S, Hutter M, Szabo B, Auwärter V (2013) Acute intoxication by synthetic cannabinoids—four case reports. Drug Test Anal 5:790–794PubMed

48.

Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwärter V (2014) Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med 128:59–64PubMed

49.

Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in herbal mixtures using LC–MS/MS techniques. J Mass Spectrom 47:54–65PubMed

50.

Shanks KG, Dahn T, Terrell AR (2012) Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 36:145–152PubMed

51.

Adamowicz P, Zuba D, Sekuła K (2013) Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int 233:320–327PubMed

52.

Saito T, Namera A, Miura N, Ohta S, Miyazaki S, Osawa M, Inokuchi S (2013) A fatal case of MAM-2201 poisoning. Forensic Toxicol 31:333–337

53.

Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, Jaskierny DJ, Meroueh C (2014) Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 38:559–562PubMed

54.

Mazzarino M, de la Torre X, Botrè F (2014) A liquid chromatography–mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples. Anal Chim Acta 837:70–82PubMed

55.

Wood DM, Dargan PI (2012) Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity. Prog Neuro-Psychopharmacol Biol Psychiatry 39:227–233

56.

Uchiyama N, Kawamura M, Kamakura H, Kikura-Hanajiri R, Goda Y (2008) Analytical data of designated substances (Shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, part II: color test and TLC (in Japanese with English abstract). Yakugaku Zasshi 128:981–987PubMed

57.

Dal Cason TA (1997) The characterization of some 3,4-methylenedioxycathinone (MDCATH) homologs. Forensic Sci Int 87:9–53

58.

Swortwood MJ, Hearn WL, DeCaprio AP (2014) Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays. Drug Test Anal 6:716–727PubMed

59.

Ellefsen KN, Anizan S, Castaneto MS, Desrosiers NA, Martin TM, Klette KL, Huestis MA (2014) Validation of the only commercially available immunoassay for synthetic cathinones in urine: randox drugs of abuse V biochip array technology. Drug Test Anal 6:728–738PubMedCentralPubMed

60.

Penders TM, Gestring RE, Vilensky DA (2012) Intoxication delirium following use of synthetic cathinone derivatives. Am J Drug Alcohol Abuse 38:616–617PubMed

61.

Zuba D (2012) Identification of cathinones and other active components of legal highs by mass spectrometric methods. Trends Anal Chem 32:15–30

62.

Matsuta S, Katagi M, Nishioka H, Kamata H, Sasaki K, Shima N, Kamata T, Miki A, Tatsuno M, Zaitsu K, Tsuboi K, Tsuchihashi H, Suzuki K (2014) Structural characterization of cathinone-type designer drugs by EI mass spectrometry (in Japanese with English abstract). Jpn J Forensic Sci Tech 19:77–89

63.

Brandt SD, Sumnall HR, Measham F, Cole J (2010) Analyses of second-generation ‘legal highs’ in the UK: initial findings. Drug Test Anal 2:377–382PubMed

64.

Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (2011) Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. Drug Test Anal 3:569–575PubMed

65.

Fornal E (2013) Identification of substituted cathinones: 3,4-methylenedioxy derivatives by high performance liquid chromatography–quadrupole time of flight mass spectrometry. J Pharm Biomed Anal 81–82:13–19PubMed

66.

Jankovics P, Váradi A, Tölgyesi L, Lohner S, Németh-Palotás J, Koszegi-Szalai H (2011) Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography–tandem mass spectrometry (LC–MS/MS) screening method for seven different methcathinone analogs. Forensic Sci Int 210:213–220PubMed

67.

Westphal F, Junge T (2012) Ring positional differentiation of isomeric N-alkylated fluorocathinones by gas chromatography/tandem mass spectrometry. Forensic Sci Int 223:97–105PubMed

68.

Meyer MR, Du P, Schuster F, Maurer HH (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high-resolution MS and its detectability in urine by GC–MS. J Mass Spectrom 45:1426–1442PubMed

69.

Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24:2706–2714PubMed

70.

Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the US. Clin Toxicol 49:499–505

71.

Ojanperä IA, Heikman PK, Rasanen IJ (2011) Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography–mass spectrometry. Ther Drug Monit 33:257–263PubMed

72.

Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC 3rd, Garg U, Pietak BR (2012) Three fatal intoxications due to methylone. J Anal Toxicol 36:444–451PubMed

73.

Saito T, Namera A, Osawa M, Aoki H, Inokuchi S (2013) SPME–GC–MS analysis of α-pyrrolidinovaleorophenone in blood in a fatal poisoning case. Forensic Toxicol 31:328–332

74.

Namera A, Urabe S, Saito T, Torikoshi-Hatano A, Shiraishi H, Arima Y, Nagao M (2013) A fatal case of 3,4-methylenedioxypyrovalerone poisoning: coexistence of α-pyrrolidinobutiophenone and α-pyrrolidinovalerophenone in blood and/or hair. Forensic Toxicol 31:338–343

75.

Wyman JF, Lavins ES, Engelhart D, Armstrong EJ, Snell KD, Boggs PD, Taylor SM, Norris RN, Miller FP (2013) Postmortem tissue distribution of MDPV following lethal intoxication by bath salts. J Anal Toxicol 37:182–185PubMed

76.

Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE (2013) Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci 58:1558–1562PubMed

77.

Shima N, Katagi M, Kamata H, Matsuta S, Nakanishi K, Zaitsu K, Kamata T, Nishioka H, Miki A, Tatsuno M, Sato T, Tsuchihashi H, Suzuki K (2013) Urinary excretion and metabolism of the newly encountered designer drug 3,4-dimethylmethcathinone in humans. Forensic Toxicol 31:101–112

78.

Uralets V, Rana S, Morgan S, Ross W (2014) Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. J Anal Toxicol 38:233–241PubMed

79.

Shima N, Katagi M, Kamata H, Matsuta S, Sasaki K, Kamata T, Nishioka H, Miki A, Tatsuno M, Zaitsu K, Ishii A, Sato T, Tsuchihashi H, Suzuki K (2014) Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol 32:59–67

80.

Swortwood MJ, Boland DM, DeCaprio AP (2013) Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Anal Bioanal Chem 405:1383–1397PubMed

81.

Concheiro M, Anizan S, Ellefsen K, Huestis MA (2013) Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography–high resolution mass spectrometry. Anal Bioanal Chem 405:9437–9448PubMed

82.

Sørensen LK (2011) Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B 879:727–736

83.

Kriikku P, Wilhelm L, Schwarz O, Rintatalo J (2011) New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int 210:195–200PubMed

84.

Maskell PD, De Paoli G, Seneviratne C, Pounder DJ (2011) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35:188–191PubMed

85.

Rust KY, Baumgartner MR, Dally AM, Kraemer T (2012) Prevalence of new psychoactive substances: a retrospective study in hair. Drug Test Anal 4:402–408PubMed

86.

Rojek S, Kłys M, Strona M, Maciow M, Kula K (2012) “Legal highs”—toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration. Forensic Sci Int 222:e1–e6PubMed

87.

Gil D, Adamowicz P, Skulska A, Tokarczyk B, Stanaszek R (2013) Analysis of 4-MEC in biological and non-biological material-three case reports. Forensic Sci Int 228:e11–e15PubMed

88.

Adamowicz P, Tokarczyk B, Stanaszek R, Slopianka M (2013) Fatal mephedrone intoxication—a case report. J Anal Toxicol 37:37–42PubMed

89.

Johnson RD, Botch-Jones SR (2013) The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in three biological matrices under various storage conditions. J Anal Toxicol 37:51–55PubMed

90.

Cosbey SH, Peters KL, Quinn A, Bentley A (2013) Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J Anal Toxicol 37:74–82PubMed

91.

Marinetti LJ, Antonides HM (2013) Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 37:135–146PubMed

92.

Adamowicz P, Gil D, Skulska A, Tokarczyk B (2013) Analysis of MDPV in blood—determination and interpretation. J Anal Toxicol 37:308–312PubMed

93.

Zuba D, Adamowicz P, Byrska B (2013) Detection of buphedrone in biological and non-biological material—two case reports. Forensic Sci Int 227:15–20PubMed

94.

Anizan S, Ellefsen K, Concheiro M, Suzuki M, Rice KC, Baumann MH, Huestis MA (2014) 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography–high resolution mass spectrometry. Anal Chim Acta 827:54–63PubMedCentralPubMed

95.

Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K (2014) Postmortem distribution of α-pyrrolidinobutiophenone in body fluids and solid tissues of a human cadaver. Leg Med 16:241–246

96.

Usui K, Aramaki T, Hashiyada M, Hayashizaki Y, Funayama M (2014) Quantitative analysis of 3,4-dimethylmethcathinone in blood and urine by liquid chromatography–tandem mass spectrometry in a fatal case. Leg Med 16:222–226

97.

Bertol E, Mari F, Berto RB, Mannaioni G, Vaiano F, Favretto D (2014) A mixed MDPV and benzodiazepine intoxication in a chronic drug abuser: determination of MDPV metabolites by LC–HRMS and discussion of the case. Forensic Sci Int 243:149–155PubMed

98.

Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K (2014) Identification and quantitation of a new cathinone designer drug PV9 in an “aroma liquid” product, antemortem whole blood and urine specimens, and a postmortem whole blood specimen in a fatal poisoning case. Forensic Toxicol 32:243–250

99.

Bijlsma L, Sancho JV, Hernández F, Niessen WMA (2011) Fragmentation pathways of drugs of abuse and their metabolites based on QTOF MS/MS and MSE^E accurate-mass spectra. J Mass Spectrom 46:865–875PubMed

100.

Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2013) K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58:1676–1680PubMedCentralPubMed

101.

Springer D, Fritschi G, Maurer HH (2003) Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography–mass spectrometry. J Chromatogr B 796:253–266

102.

Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH (2009) New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 44:952–964PubMed

103.

Tyrkkö E, Pelander A, Ketola RA, Ojanperä I (2013) In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal Bioanal Chem 405:6697–6709PubMed

104.

Namera A, Konuma K, Kawamura M, Saito T, Nakamoto A, Yahata M, Ohta S, Miyazaki S, Shiraishi H, Nagao M (2014) Time-course profile of urinary excretion of intravenously administered α-pyrrolidinovalerophenone and α-pyrrolidinobutiophenone in a human. Forensic Toxicol 32:68–74

105.

Kovács K, Tóth AR, Kereszty EM (2012) A new designer drug: methylone related death. Orv Hetil 153:271–276PubMed

106.

Cawrse BM, Levine B, Jufer RA, Fowler DR, Vorce SP, Dickson AJ, Holler JM (2012) Distribution of methylone in four postmortem cases. J Anal Toxicol 36:434–439PubMed

107.

Torrance H, Cooper G (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202:e62–e63PubMed

108.

Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AG (2011) A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci Int 206:e93–e95PubMed

109.

Hasegawa K, Suzuki O, Wurita A, Minakata K, Yamagishi I, Nozawa H, Gonmori K, Watanabe K (2014) Postmortem distribution of α-pyrrolidinovalerophenone and its metabolite in body fluids and solid tissues in a fatal poisoning case measured by LC–MS–MS with the standard addition method. Forensic Toxicol 32:225–234

110.

Murray BL, Murphy CM, Beuhler MC (2012) Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 8:69–75PubMedCentralPubMed

111.

Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR (2013) Methylenedioxypyrovalerone (“bath salts”), related death: case report and review of the literature. J Forensic Sci 58:1654–1659PubMed

Title: Comprehensive review of the detection methods for synthetic cannabinoids and cathinones
Authors: Akira Namera
Maho Kawamura
Akihiro Nakamoto
Takeshi Saito
Masataka Nagao
Publication date: 01-07-2015
Publisher: Springer Japan
Published in: Forensic Toxicology / Issue 2/2015
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-015-0270-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comprehensive review of the detection methods for synthetic cannabinoids and cathinones

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

A case of fatal intoxication due to the new designer drug 25B-NBOMe

Differentiation of regioisomeric chloroamphetamine analogs using gas chromatography–chemical ionization-tandem mass spectrometry

Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver

Diphenidine and its metabolites in blood and urine analyzed by MALDI-Q-TOF mass spectrometry

Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues

Urinary excretion and metabolism of the α-pyrrolidinophenone designer drug 1-phenyl-2-(pyrrolidin-1-yl)octan-1-one (PV9) in humans